File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Safety of tocilizumab in patients with rheumatoid arthritis (RA) and a median treatment duration of 2.6 years

TitleSafety of tocilizumab in patients with rheumatoid arthritis (RA) and a median treatment duration of 2.6 years
Authors
Xu, JTaylor, ALLouthrenoo, WMok, MYKissel, KVernon, EVan Vollenhoven, RF
KeywordsMedical sciences
Rheumatology
Issue Date2010
PublisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwell-synergy.com/loi/ijrd
Citation
The 14th Congress of Asia Pacific League of Associations for Rheumatology, Hong Kong, China, 11-15 July 2010. In International Journal of Rheumatic Diseases, 2010, v. 13 suppl. 1, p. 98, abstract no. 0207 How to Cite?
DOI: http://dx.doi.org/10.1111/j.1756-185X.2010.01499.x
AbstractOBJECTIVE: The safety of tocilizumab has been demonstrated in RA patients in phase 3 clinical trials. The objective of this analysis was to assess the longer-term safety of tocilizumab using pooled data from ongoing, long-term extension studies. METHODS: Patients included received ‡1 dose of tocilizumab (4 mg/kg or 8 mg/kg) in four 24-week phase 3 clinical trials (OPTION, TOWARD, RADIATE, AMBITION), in a 2-year, phase 3 clinical trial (LITHE), in a phase 1 study …
DescriptionClinical Research: 2.4 Rheumatoid arthritis – non TNFα biological therapies
Persistent Identifierhttp://hdl.handle.net/10722/129842
ISSN
1756-1841
2021 Impact Factor: 2.558
2020 SCImago Journal Rankings: 0.795

 

DC FieldValueLanguage
dc.contributor.authorXu, Jen_US
dc.contributor.authorTaylor, ALen_US
dc.contributor.authorLouthrenoo, Wen_US
dc.contributor.authorMok, MYen_US
dc.contributor.authorKissel, Ken_US
dc.contributor.authorVernon, Een_US
dc.contributor.authorVan Vollenhoven, RFen_US
dc.date.accessioned2010-12-23T08:42:50Z-
dc.date.available2010-12-23T08:42:50Z-
dc.date.issued2010en_US
dc.identifier.citationThe 14th Congress of Asia Pacific League of Associations for Rheumatology, Hong Kong, China, 11-15 July 2010. In International Journal of Rheumatic Diseases, 2010, v. 13 suppl. 1, p. 98, abstract no. 0207en_US
dc.identifier.issn1756-1841-
dc.identifier.urihttp://hdl.handle.net/10722/129842-
dc.descriptionClinical Research: 2.4 Rheumatoid arthritis – non TNFα biological therapies-
dc.description.abstractOBJECTIVE: The safety of tocilizumab has been demonstrated in RA patients in phase 3 clinical trials. The objective of this analysis was to assess the longer-term safety of tocilizumab using pooled data from ongoing, long-term extension studies. METHODS: Patients included received ‡1 dose of tocilizumab (4 mg/kg or 8 mg/kg) in four 24-week phase 3 clinical trials (OPTION, TOWARD, RADIATE, AMBITION), in a 2-year, phase 3 clinical trial (LITHE), in a phase 1 study …-
dc.languageengen_US
dc.publisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwell-synergy.com/loi/ijrd-
dc.relation.ispartofInternational Journal of Rheumatic Diseasesen_US
dc.rightsThe definitive version is available at www3.interscience.wiley.com-
dc.subjectMedical sciences-
dc.subjectRheumatology-
dc.titleSafety of tocilizumab in patients with rheumatoid arthritis (RA) and a median treatment duration of 2.6 yearsen_US
dc.typeConference_Paperen_US
dc.identifier.emailMok, MY: temy@hkucc.hku.hken_US
dc.identifier.authorityMok, MY=rp00490en_US
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1111/j.1756-185X.2010.01499.x-
dc.identifier.hkuros177410en_US
dc.identifier.volume13en_US
dc.identifier.issuesuppl. 1-
dc.identifier.spage98, abstract no. 0207en_US
dc.identifier.epage98, abstract no. 0207-
dc.description.otherThe 14th Congress of Asia Pacific League of Associations for Rheumatology, Hong Kong, China, 11-15 July 2010. In International Journal of Rheumatic Diseases, 2010, v. 13 suppl. 1, p. 98, abstract no. 0207-
dc.identifier.issnl1756-1841-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats